Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib

Ann Hematol. 2019 Jan;98(1):205-207. doi: 10.1007/s00277-018-3381-y. Epub 2018 May 26.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenine / analogs & derivatives
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Autoimmune Diseases* / chemically induced
  • Autoimmune Diseases* / diagnostic imaging
  • Autoimmune Diseases* / drug therapy
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / diagnostic imaging
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Male
  • Middle Aged
  • Myelitis* / chemically induced
  • Myelitis* / diagnostic imaging
  • Myelitis* / drug therapy
  • Piperidines
  • Prednisone / administration & dosage
  • Prednisone / adverse effects
  • Pyrazoles* / administration & dosage
  • Pyrazoles* / adverse effects
  • Pyrimidines* / administration & dosage
  • Pyrimidines* / adverse effects
  • Rituximab
  • Vincristine / administration & dosage
  • Vincristine / adverse effects

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • R-CHOP protocol
  • ibrutinib
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Adenine
  • Prednisone